Biosimilar User Fee Collections Drop Below Estimates, But FDA Is Not Worried
The agency hopes application volume increases, but warns the biosimilar user fee revenue will remain volatile.
You may also be interested in...
In congressional testimony, outgoing Commissioner Scott Gottlieb says FDA already has "a lot of applications in-house" and robust interest when asked about the 2020 transition of insulin from regulation as a drug to a biologic.
US FDA sets a new monthly record for full approvals, but industry group argues that approvals alone aren't creating more generic competition in the market.
Three-to-five year timeline needed to develop algorithms does not engender confidence that new version of formula, which historically pushed user fee rates higher, will be ready before PDUFA VII begins.